SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

A strong third-quarter earnings report and first public-company profit, driven largely by rapid growth in AI compute, have fueled a sharp bullish reaction and talk of a SpaceX re-rating. Traders are debating whether the AI opportunity and ambitious expansion plans justify the valuation, given heavy capital spending and cash-burn concerns; a possible Tesla merger is also being discussed but remains unconfirmed.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs earnings beat was overshadowed by a softer Q4 outlook and cuts to its advertising and free-cash-flow expectations, renewing concerns about slowing growth. Traders are divided between dip buyers pointing to the profitable quarter and bears citing weaker guidance, ad execution and streaming competition.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary quarterly update sharply raised its revenue and gross-margin outlook on strong AI-platform demand, driving a sharp after-hours rally. Traders largely welcomed the stronger outlook and debated whether it can hold, with some cautioning that execution, cash flow and sustained margins still need confirmation.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

SpaceXs strong results and AI infrastructure spending, alongside Super Micros higher preliminary sales outlook, have revived discussion that demand for Nvidia-powered data centers remains robust. Bulls see support for the AI buildout, while skeptics question the returns on heavy capital spending and point to Nvidias weak recent price action; reported Chinese chip orders are another demand signal, though export restrictions may limit fulfillment.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A sharp, high-volume rebound has intensified attention on SELLASs Phase 3 REGAL trial, with traders anticipating an update on the 80th survival event and the final analysis of its GPS treatment for AML; the last publicly cited event count was 78, and no new results are confirmed here. Bullish speculation about an imminent announcement or buyout contrasts with skepticism that the move is a volatile rally without fresh news and that the trial outcome remains uncertain.

Sui s a Layer 1 blockchain developed by Mysten Labs, a team founded by former lead engineers from Meta’s blockchain research division. It is designed for global adoption by providing a secure, high-speed environment for digital asset ownership and removing technical barriers for Web3 applications. The platform utilizes the Move programming language to create a safe framework and supports horizontal scaling to keep fees stable and speeds high as the network grows. Significant institutional support comes from major venture capital firms including Andreessen Horowitz, Coinbase Ventures, Circle Ventures, and YZi Labs.  The system functions by organizing data into independent objects rather than a single ledger of accounts. This object-centric data model enables parallel execution, allowing the network to process many transactions simultaneously instead of waiting for one to finish before starting the next. This architecture is built for rapid transaction finalization to ensure near-instant results. To maintain long-term stability, the network collects fees into a storage fund that rewards validators for keeping data on the network indefinitely.  Sui offers several advanced tools including zkLogin for easier account access and sponsored transactions that allow users to interact with apps without managing complex wallets or immediate fees. Developers can also create tailored object types that work across the entire network, which encourages innovation and deep composability. These features are designed to create a more user-friendly experience for interacting with decentralized applications and digital games.  The SUI token is central to the ecosystem, serving as the primary asset for transaction fees and on-chain utility within decentralized exchanges and lending platforms. Users participate in a proof-of-stake mechanism by locking their tokens to support validators and secure the blockchain in exchange for rewards. Additionally, token holders have a role in governance, allowing them to participate in voting on network rules and future protocol upgrades. Value moves through the system through these staking rewards and transaction fees to ensure the platform scales sustainably

SUI is drawing attention for volatile price swings around the $1 level, with traders watching for a sustained rebound and debating whether recent gains can continue. Bullish arguments cite ecosystem developments in AI and institutional use, while skeptics point to token unlocks, weak relative performance, and concerns about the network.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE is under pressure after beating quarterly estimates and raising its outlook, as investors focus on rising costs, weaker cash conversion and a loss in its insurance business. Traders are frustrated by another selloff on strong results, while bullish voices view the pullback as a buying opportunity given robust aerospace demand and orders.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is trading amid a volatile neocloud and AI-infrastructure debate: traders tied an earlier sector bounce to SpaceXs strong compute-demand outlook, while subsequent selling has focused on financing risks and weakness across the group. Bulls argue that sustained demand and Nebiuss comparatively sturdier funding distinguish it from peers; bears remain concerned about the sectors debt exposure.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Ubers agreement to acquire corporate-catering platform ezCater for $2.3 billion is prompting debate over whether it can broaden Uber Eats and drive growth or represents costly M&A. Traders are also focused on the shares persistent weakness around $70, with some arguing autonomous-vehicle competition is weighing on sentiment.

Boost Run, Inc. is a provider of scalable cloud infrastructure purpose-built for enterprise AI and high-performance computing workloads. The platform delivers GPU compute, CPU nodes, managed Kubernetes orchestration, and shared storage through an intuitive management console and a robust API layer, enabling organizations to provision and scale resources across thousands of nodes in minutes. The company was founded on September 5, 2025 and is headquartered in Northbrook, IL.

Boost Run Inc. - Ordinary Shares - Class A

Boost Run Inc.

BRUN is drawing attention amid a sharp selloff in small-cap neocloud and AI infrastructure stocks, with traders pointing to rising yields and doubts about AI spending returns, hardware depreciation, and financing. The debate is whether the decline is sector-driven or reflects BRUN-specific execution risk; bullish traders cite its contracted backlog and look to Q3 results for evidence that demand can translate into revenue and cash flow.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade

The consensus price target hints at a 124.6% upside potential for Vor Biopharma (VOR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Jefferies Financial Group Upgrades Vor Biopharma (NASDAQ:VOR) to Strong-Buy

Jefferies Financial Group upgraded shares of Vor Biopharma to a "strong-buy" rating in a report on Thursday...

Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from Brokerages

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the thirteen analysts that are presently covering the stock, Marketbeat reports. One...

Vor Biopharma Inc. (NASDAQ:VOR) Short Interest Down 17.3% in April

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) was the target of a significant drop in short interest in the month of April. As of April 15th, there was short interest totaling 4,706,707 shares, a...

Vor Biopharma (NASDAQ:VOR) Director Ra Capital Management, L.P. Sells 165,150 Shares

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) Director Ra Capital Management, L.P. sold 165,150 shares of the business's stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $15.77, for a total value of $2,604,415.50. Following the sale, the director...

Vor Biopharma (NASDAQ:VOR) Director Sells $2,711,856.51 in Stock

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) Director Ra Capital Management, L.P. sold 171,963 shares of the stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $15.77, for a total transaction of $2,711,856.51. Following the sale, the...

Vor Biopharma (NASDAQ:VOR) Director Sells $7,462,931.08 in Stock

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) Director Ra Capital Management, L.P. sold 458,411 shares of the firm's stock in a transaction that occurred on Friday, April 17th. The shares were...

Insider Selling: Vor Biopharma (NASDAQ:VOR) Director Sells 171,963 Shares of Stock

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) Director Ra Capital Management, L.P. sold 171,963 shares of the company's stock in a transaction dated Monday, April 20th. The stock was sold at an...

Vor Biopharma (NASDAQ:VOR) Shares Down 4.4% - Here's What Happened

Vor Biopharma (NASDAQ:VOR) Shares Down 4.4% - Here's What Happened...

Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 117% in Vor Biopharma (VOR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Vor Biopharma, Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. It is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Boston, MA.

Vor Biopharma Inc

VOR Shares Rally Over 40% In Pre-Market Trade After JPMorgan Initiates Bullish Coverage 

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Vor Biopharma shares surged over&nbsp;40%&nbsp;after JPMorgan initiated coverage of the company.&nbsp;</li><li>JPMorgan’s bullish stance comes amid Phase 3 clinical trial success for an autoimmune drug, telitacicept.&nbsp;</li><li>On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ while message volume rose to ‘extremely high’ levels.</li></ul>Shares of Vor Biopharma Inc. (VOR) rallied over 40% on Tuesday in premarket trading after JPMorgan initiated coverage of the clinical-stage biopharma company with a bullish stance.&nbsp;In a note on Tuesday, as cited by TheFly, JPMorgan awarded&nbsp;<a href="https://stocktwits.com/symbol/VOR">VOR</a> with an ‘Overweight’ rating and set a price target of $43. The firm said that it views VOR’s telitacicept, a recombinant fusion protein that is intended to treat autoimmune diseases, as "highly de-risked" across a range of indications.&nbsp;<h2 class="st-heading-2">Tapping Market Gaps</h2>JPMorgan’s coverage comes amid the pharma company’s success in its autoimmune disease treatment plans. In its latest quarterly results, VOR noted that telitacicept has “demonstrated consistent results on multiple efficacy endpoints, durable benefit, and a favorable safety profile”.&nbsp;VOR has a "significant valuation disconnect", JPMorgan said in its note, highlighting the probability-adjusted value of telitacicept to treat chronic conditions of myasthenia gravis and primary Sjogren's disease alone. The firm added that VOR, while focused on global indications that are less competitive, still has an unmet need that is significant.&nbsp;In other news, Vor Biopharma&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.vorbio.com/news-releases/news-release-details/vor-bio-announces-pricing-public-offering-100-million-common">announced</a> a $100 million public offering of common stock priced at $10 per share in November.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around VOR jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1286/155;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_09_at_6_11_06_PM_png_fd2a6ad6c4.webp" alt="On Stocktwits, retail sentiment around VOR jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels." width="1286" height="155"></figure>One user on the platform predicted that VOR’s share price could go up to $20. The stock was trading around $10 at the time of writing.&nbsp;<a href="https://stocktwits.com/apux/message/638580684">https://stocktwits.com/apux/message/638580684</a>Shares of VOR have fallen almost 60% in the past one year.For updates and corrections, email newsroom[at]stocktwits[dot]com&nbsp;

Young female scientist working in laboratory (Representative image courtesy of Solskin via Getty Images)

The firm gave Vor Biopharma an ‘Overweight’ rating with a price target of $43. 

VOR Shares Rally Over 40%In Pre-Market Trade After JPMorgan Initiates Bullish Coverage 

The firm gave Vor Biopharma an ‘Overweight’ rating with a price target of $43. 


Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

VOR Vor Biopharma Inc

Fundamentals

Latest VOR News